Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0IM6O
|
||||
| Former ID |
DIB008179
|
||||
| Drug Name |
Talactoferrin
|
||||
| Synonyms |
Talactoferrin (topical)
|
||||
| Indication | Diabetic foot ulcer [ICD9: 707; ICD10:L88-L89] | Phase 3 | [1] | ||
| Company |
Agennix AG
|
||||
| Target and Pathway | |||||
| Target(s) | Lactotransferrin | Target Info | Modulator | [2] | |
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | ||||
| TCR Signaling Pathway | |||||
| Reactome | ROS production in response to bacteria | ||||
| Amyloid formation | |||||
| WikiPathways | Latent infection of Homo sapiens with Mycobacterium tuberculosis | ||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT00706862) Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer. U.S. National Institutes of Health. | ||||
| REF 2 | Talactoferrin alfa, a recombinant human lactoferrin promotes healing of diabetic neuropathic ulcers: a phase 1/2 clinical study. Am J Surg. 2007 Jan;193(1):49-54. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.